Non-Hodgkin's lymphomas, version 2.2014.

Published

Journal Article

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

Full Text

Duke Authors

Cited Authors

  • Zelenetz, AD; Gordon, LI; Wierda, WG; Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Bellam, N; Byrd, JC; Czuczman, MS; Fayad, LE; Fisher, RI; Glenn, MJ; Harris, NL; Hoppe, RT; Horwitz, SM; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Nademanee, A; Porcu, P; Press, O; Rabinovitch, R; Reddy, N; Reid, E; Sokol, L; Swinnen, LJ; Tsien, C; Vose, JM; Yahalom, J; Zafar, N; Dwyer, M; Sundar, H

Published Date

  • June 2014

Published In

Volume / Issue

  • 12 / 6

Start / End Page

  • 916 - 946

PubMed ID

  • 24925202

Pubmed Central ID

  • 24925202

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2014.0086

Language

  • eng

Conference Location

  • United States